Chronic Sialorrhea Market

Market Overview:

The 7 major chronic sialorrhea markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.15% during 2024-2034.

The chronic sialorrhea market has been comprehensively analyzed in IMARC's new report titled "Chronic Sialorrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic sialorrhea refers to a nerve and muscle condition that causes an unintentional loss of saliva from the mouth. This disease can contribute to drooling if there's an inability to keep the mouth closed or difficulties swallowing the excess saliva, which can result in excessive spitting. The common symptoms of the ailment include foul odor, dehydration, skin breakdown around the mouth, chapped lips, increased tiredness, etc. Individuals suffering from chronic sialorrhea may also experience infection from skin breakdown, embarrassment, sleep problems, reduced social interactions, irritated skin, etc. Diagnosing this illness typically requires identifying the patient's symptoms, medical history, and clinical screening examinations. The healthcare provider performs neurological workups, including fiberoptic endoscopic evaluation of swallowing (FEES), to support the diagnosis. Additionally, a radiological procedure known as videofluoroscopy, which provides direct, dynamic information on the genesis and aids therapy selection, is further utilized to confirm the prognosis.

The increasing prevalence of neuromuscular or sensory dysfunction, such as cerebral palsy, Parkinson's disease, mental retardation, stroke, etc., which affects the ability to perform the normal compensatory mechanism for excessive salivation, is primarily driving the chronic sialorrhea market. Moreover, the escalating requirement for anticholinergic agents, like glycopyrrolate, tropicamide, benztropine, scopolamine, etc., to treat chronic sialorrhea is further creating a positive outlook for the market. These medications mainly decrease saliva production through the parasympathetic autonomic nervous system by inhibiting salivation and blocking cholinergic muscarinic receptors. Apart from this, the emerging popularity of botulinum toxin injection, owing to its numerous benefits, including limited invasiveness, fewer side effects with greater effectiveness, and improved quality of life in patients, is also bolstering the market growth. Furthermore, the widespread adoption of oral prosthetic devices, such as dental appliances and chin cups, to help with lip closure, tongue positioning, and swallowing is acting as another significant growth-inducing factor. In addition to this, the rising popularity of transoral endoscopic submandibular ganglion neurectomy, since it can provide symptom relief in patients who have failed traditional pharmacological therapies, is expected to drive the chronic sialorrhea market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the chronic sialorrhea market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic sialorrhea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic sialorrhea market in any manner.

Key Highlights:

• The incidence of chronic sialorrhea varies around 0.6% and is most typically encountered in distressed children with cerebral palsy or other neurological abnormalities.
• The prevalence of sialorrhea is reported to be 10-58% in cerebral palsy.
• The frequency of mild, moderate, and severe sialorrhea varied by severity, with 25.1%, 11.2%, and 10.5%, respectively.

Drugs:

Xeomin (incobotulinumtoxinA) is a prescription medication that is injected into muscles and used to treat boosted muscle stiffness in the arm of patients with upper limb spasticity, neck pain, and the abnormal head position associated with chronic sialorrhea in adults, and abnormal spasm of the eyelids in patients who have previously received onabotulinumtoxinA (Botox).

MYOBLOC (rimabotulinumtoxinB) injection is the first and only approved botulinum toxin Type B injectable used to reduce the intensity of neck pain and abnormal head position in adults. It is a prescription drug that is injected into the salivary glands (submandibular and parotid glands) to treat chronic sialorrhea in adults.

Cuvposa (glycopyrrolate) oral solution is an anticholinergic medication used to treat chronic excessive drooling caused by neurologic abnormalities in children. This therapeutic candidate is developed by Sciele Pharma, a Shionogi group company.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic sialorrhea market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic sialorrhea market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic sialorrhea marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chronic sialorrhea market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chronic sialorrhea market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chronic sialorrhea market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of chronic sialorrhea across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic sialorrhea by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic sialorrhea by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with chronic sialorrhea across the seven major markets?
• What is the size of the chronic sialorrhea patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chronic sialorrhea?
• What will be the growth rate of patients across the seven major markets?
   

Chronic Sialorrhea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic sialorrhea drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic sialorrhea market?
• What are the key regulatory events related to the chronic sialorrhea market?
• What is the structure of clinical trial landscape by status related to the chronic sialorrhea market?
• What is the structure of clinical trial landscape by phase related to the chronic sialorrhea market?
• What is the structure of clinical trial landscape by route of administration related to the chronic sialorrhea market?